MGC Diagnostics Corporation Announces National Jewish Health Selects the Company as Preferred Provider for Cardiopulmonary Diagnostic Instrumentation

SAINT PAUL, Minn., Feb. 5, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today announced that National Jewish Health has selected MGC Diagnostics as its preferred provider of cardiopulmonary diagnostic instrumentation. Based in Denver, Colorado, National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. National Jewish Health has been ranked by U.S.News & World Report as the number one respiratory hospital in the nation for the past 15 consecutive years. Founded in 1899 as a nonprofit hospital, National Jewish Health remains the only facility in the world dedicated exclusively to these disorders.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

MGC Diagnostics has shipped a new fleet of cardiorespiratory devices; including body plethysmography, gas exchange and spirometer systems to the National Jewish Health main campus in Denver. Additionally, the Company is providing a comprehensive electronic medical interface, extending security and accessibility of cardiorespiratory patient data throughout the National Jewish Health network.

MGC Diagnostics, ranked 'Best-In-Class' over a two year trend by MD Buyline's User Satisfaction Report, is focused on providing unmatched service and support, relentlessly making improvements, and anticipating and solving unmet needs.

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC Diagnostics, commented "MGC Diagnostics is pleased to have been selected by National Jewish Health, one of the world's leading medical research and treatment centers. We believe this win validates our technical innovation in cardiorespiratory health and our ability to provide leading medical facilities seamless communications with electronic medical records critical to improved workflows. We are excited to provide long term solutions that will assist them in maintaining their market leading status in respiratory care."

About National Jewish Health

National Jewish Health is known worldwide for treatment of patients with respiratory, cardiac, immune and related disorders, and for groundbreaking medical research. Founded in 1899 as a nonprofit hospital, National Jewish Health remains the only facility in the world dedicated exclusively to these disorders. Since 1998, U.S. News & World Report has ranked National Jewish Health the number one respiratory hospital in the nation.

About MGC Diagnostics

MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forwardlooking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forwardlooking statements, the Company claims the protection of the safe harbor for forwardlooking statements contained in federal securities laws. These forwardlooking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forwardlooking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

SOURCE MGC Diagnostics Corporation